Literature DB >> 26426530

The Impact of Misuse and Diversion of Opioid Substitution Treatment Medicines: Evidence Review and Expert Consensus.

Jens Reimer1, Nat Wright, Lorenzo Somaini, Carlos Roncero, Icro Maremmani, Neil McKeganey, Richard Littlewood, Peter Krajci, Hannu Alho, Oscar D'Agnone.   

Abstract

BACKGROUND/AIMS: Opioid substitution treatment (OST) improves outcomes in opioid dependence. However, controlled drugs used in treatment may be misused or diverted, resulting in negative treatment outcomes. This review defines a framework to assess the impact of misuse and diversion.
METHODS: A systematic review of published studies of misuse and diversion of OST medicines was completed; this evidence was paired with expert real-world experience to better understand the impact of misuse and diversion on the individual and on society.
RESULTS: Direct impact to the individual includes failure to progress in recovery and negative effects on health (overdose, health risks associated with injecting behaviour). Diversion of OST has impacts on a community that is beyond the intended OST recipient. The direct impact includes risk to others (unsupervised use; unintended exposure of children to diverted medication) and drug-related criminal behavior. The indirect impact includes the economic costs of untreated opioid dependence, crime and loss of productivity.
CONCLUSION: While treatment for opioid dependence is essential and must be supported, it is vital to reduce misuse and diversion while ensuring the best possible care. Understanding the impact of OST misuse and diversion is key to defining strategies to address these issues.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 26426530     DOI: 10.1159/000438988

Source DB:  PubMed          Journal:  Eur Addict Res        ISSN: 1022-6877            Impact factor:   3.015


  11 in total

1.  Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials.

Authors:  Aksana K Jones; Eliford Ngaimisi; Mathangi Gopalakrishnan; Malcolm A Young; Celine M Laffont
Journal:  Clin Pharmacokinet       Date:  2020-11-02       Impact factor: 6.447

2.  The use of diverted pharmaceutical opioids is associated with reduced risk of fentanyl exposure among people using unregulated drugs in Vancouver, Canada.

Authors:  M Eugenia Socias; Cameron Grant; Kanna Hayashi; Geoff Bardwell; Mary Clare Kennedy; M-J Milloy; Thomas Kerr
Journal:  Drug Alcohol Depend       Date:  2021-09-25       Impact factor: 4.492

Review 3.  Challenges of Using Methadone in the Indian Pain and Palliative Care Practice.

Authors:  Vidya Viswanath; Gayatri Palat; Srini Chary; Ann Broderick
Journal:  Indian J Palliat Care       Date:  2018-01

4.  CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort.

Authors:  Concetta Dagostino; Massimo Allegri; Valerio Napolioni; Simona D'Agnelli; Elena Bignami; Antonio Mutti; Ron Hn van Schaik
Journal:  Pharmgenomics Pers Med       Date:  2018-10-24

5.  The complex relation between access to opioid agonist therapy and diversion of opioid medications: a case example of large-scale misuse of buprenorphine in the Czech Republic.

Authors:  Viktor Mravčík; Barbara Janíková; Barbora Drbohlavová; Petr Popov; Alessandro Pirona
Journal:  Harm Reduct J       Date:  2018-12-04

6.  Buprenorphine-based opioid substitution therapy in India: A few observations, thoughts, and opinions.

Authors:  Abhishek Ghosh; Debasish Basu; Ajit Avasthi
Journal:  Indian J Psychiatry       Date:  2018 Jul-Sep       Impact factor: 1.759

7.  Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.

Authors:  Björn Johnson; Torkel Richert
Journal:  Harm Reduct J       Date:  2019-05-02

8.  Developments in Drug Addiction During COVID-19-An Austrian Perspective Based on a Clinical Sample.

Authors:  Isabella Fuchs-Leitner; Kurosch Yazdi; Nikolas W Gerstgrasser; Jan Rosenleitner
Journal:  Front Psychiatry       Date:  2020-11-27       Impact factor: 4.157

9.  Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study.

Authors:  Eugenia Oviedo-Joekes; Scott MacDonald; Charles Boissonneault; Kelli Harper
Journal:  Subst Abuse Treat Prev Policy       Date:  2021-03-05

10.  Opioid and Polydrug Use Among Patients in Opioid Maintenance Treatment.

Authors:  Siv-Elin Leirvaag Carlsen; Linn-Heidi Lunde; Torbjørn Torsheim
Journal:  Subst Abuse Rehabil       Date:  2020-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.